Reengineering Ponatinib to Minimize Cardiovascular Toxicity

Small molecule tyrosine kinase inhibitors (TKI) have revolutionized cancer treatment and greatly improved patient survival. However, life-threatening cardiotoxicity of many TKIs has become a major concern. Ponatinib (ICLUSIG) was developed as an inhibitor of the BCR-ABL oncogene and is among the mos...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2022-08, Vol.82 (15), p.2777-2791
Hauptverfasser:	Hnatiuk, Anna P, Bruyneel, Arne A N, Tailor, Dhanir, Pandrala, Mallesh, Dheeraj, Arpit, Li, Wenqi, Serrano, Ricardo, Feyen, Dries A M, Vu, Michelle M, Amatya, Prashila, Gupta, Saloni, Nakauchi, Yusuke, Morgado, Isabel, Wiebking, Volker, Liao, Ronglih, Porteus, Matthew H, Majeti, Ravindra, Malhotra, Sanjay V, Mercola, Mark
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - adverse effects Cardiotoxicity - drug therapy Cardiotoxicity - etiology Cardiotoxicity - prevention & control Drug Resistance, Neoplasm Fusion Proteins, bcr-abl - genetics Humans Imidazoles Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Protein Kinase Inhibitors - adverse effects Pyridazines - pharmacology Pyridazines - therapeutic use Translational Science
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!